Renal failure in cirrhotic patients
- 1 December 2002
- journal article
- clinical trial
- Published by Ovid Technologies (Wolters Kluwer Health) in European Journal of Gastroenterology & Hepatology
- Vol. 14 (12), 1363-1368
- https://doi.org/10.1097/00042737-200212000-00013
Abstract
Renal failure secondary to hepatorenal syndrome or to organic renal disease occurs frequently in cirrhotic patients with portal hypertension. The present prospective study investigates the usefulness of terlipressin in both the diagnostic and the therapeutic approach to cirrhotics with renal failure.Sixteen patients were studied: 11 with hepatorenal syndrome type 2 (group 1) and five with organic renal disease (group 2). All received terlipressin (1 mg/4 h intravenously) for 7 days. Subsequently, 12 patients (nine from group 1 and three from group 2) underwent a transjugular intrahepatic portosystemic shunt.Terlipressin significantly improved renal function (serum creatinine, 1.8 +/- 0.8 versus 2.4 +/- 0.9 mg/dl; blood creatinine clearance, 53 +/- 8 versus 21.3 +/- 8.7 ml/min; P < 0.05) in group 1 [8/11 patients (73%) versus 1/5 (20%) of group 2; P < 0.05]. The only patient in group 2 who responded to terlipressin had a mixed renal dysfunction. Renal function improved significantly after transjugular portosystemic shunt in all patients who responded to terlipressin.Terlipressin administration significantly improves renal function in cirrhotic patients with hepatorenal syndrome type 2 but not in organic kidney failure. By providing the critical information that a patient's kidney function is (or is not) reversible, a trial with terlipressin may be useful when selecting cirrhotic patients with renal failure as candidates for a transjugular intrahepatic portosystemic shunt or liver transplantation.Keywords
This publication has 21 references indexed in Scilit:
- Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndromeJournal of Hepatology, 2000
- Complications of cirrhosis. II. Renal and circulatory dysfunction. Lights and shadows in an important clinical problemJournal of Hepatology, 2000
- Beneficial effects of the 2-day administration of terlipressin in patients with cirrhosis and hepatorenal syndromeJournal of Hepatology, 1998
- Pathophysiology of Renal Dysfunction in CirrhosisDigestion, 1998
- Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansionHepatology, 1998
- Type II mixed cryoglobulinaemia, hepatitis C virus infection, and glomerulonephritisNephrology Dialysis Transplantation, 1996
- Peripheral Arterial Vasodilation: Determinant of Functional Spectrum of CirrhosisSeminars in Liver Disease, 1994
- Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascitesGastroenterology, 1993
- Hepatitis B infection and renal disease: Clinical, immunopathogenetic and therapeutic considerationsKidney International, 1990
- Peripheral arterial vasodilation hypothesis: A proposal for the initiation of renal sodium and water retention in cirrhosisHepatology, 1988